Skip to main content

View full-text article in PMC

. 2018 Mar 27;9(23):16297–16310. doi: 10.18632/oncotarget.24631

Table 3. Relation of ALK5-FL, ALK5-ICD, pSMAD2/3 and PAI-1 protein levels to categorized clinicopathological parameters in ccRCC VHL-Low.

Parameter	ALK5-FL			ALK5-ICD			pSMAD2/3			PAI-1
Parameter	n^a	Mean Rank	P-Value^b	n^a	Mean Rank	P-Value^b	n^a	Mean Rank	P-Value^b	n^a	Mean Rank	P-Value^b
Grade
I (I+II)	34	30.85		34	30.49		34	30.03		34	28
			0.128			0.093			0.061			0.007
II (III+IV)	34	38.15		34	38.51		34	38.97		34	41
TNM Stage
Early Stage (I+II)	38	28.50		38	29.53		38	26.70		38	26.49
			0.005			0.019			0.000			0.000
Advanced Stage (III+IV)	30	42.10		30	40.80		30	44.38		30	44.65
Tumor size (mm)
<70	39	27		39	29.05		39	28.12		39	27.33
			0.000			0.008			0.002			0.001
>70	29	44.59		29	41.83		29	43.09		29	44.14

^a Number of patients.

^b Groups were compared using Mann-Whitney U test (significant at P<0.05).